Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients With Muscle-Invasive Bladder Cancer
Withdrawn before enrolling · Not applicable
Conditions studied: Infiltrating Bladder Urothelial Carcinoma
In brief
This research trial studies quality of life after bladder-preservation chemotherapy and radiation therapy (chemo-radiotherapy) in patients with bladder cancer that has spread into or through the muscle layer of the bladder (muscle-invasive bladder cancer). Bladder-preservation chemo-radiotherapy is a standard treatment for patients with muscle-invasive bladder cancer, however, chemo-radiotherapy may cause urinary tract, bowel, and sexual late side effects that negatively affect patients' quality of life. Studying quality-of-life in patients with muscle-invasive bladder cancer after chemo-radiotherapy may help identify the long-term side effects of treatment and may help plan the best treatment in the future and improve patients' quality of life.
Key facts
- Study ID
- NCT02688348
- Run by
- Jonsson Comprehensive Cancer Center
- People needed
- 0
- Starts
- 2015-04-22
- Expected to finish
- 2019-02-28
- Last updated by the study team
- 2020-07-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically confirmed muscle-invasive urothelial cancer (no histology will be excluded)
- No pelvic nodal metastases or distant metastases (based on computed tomography [CT], positron emission tomography [PET] or magnetic resonance imaging [MRI])
- Karnofsky performance status (KPS) >= 70
- Ability to understand, and willingness to sign, the written informed consent
- Patient will have either opted for bladder-sparing treatment as compared to radical cystectomy, or deemed medically inoperable
- Following the recent recommendations from the International Consultation on Urological Diseases-European Association of Urology International Consultation on Bladder Cancer, eligible patients will be those with no hydronephrosis, no extensive carcinoma in situ (CIS), and no tumor invasion into the stroma of the prostate
You may not qualify if…
- Patients with any evidence of distant metastases
- Prior pelvic radiotherapy
- History of Crohn's disease or ulcerative colitis
- Unable to receive chemotherapy
- Histologies other than urothelial (eg. squamous cell carcinoma, adenocarcinoma, small cell)
Where it is running
- UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.